{"brief_title": "A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow Transplant", "brief_summary": "To determine whether zidovudine (AZT) in conjunction with bone marrow transplantation prevents the reinfection of donor hematopoietic/lymphoid cells in patients with positive HTLV III antibody and large cell/diffuse histiocytic lymphoma. Patients who are candidates will be evaluated for HTLV III activity and drug levels.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Zidovudine", "criteria": "Exclusion Criteria Co-existing Condition: Patients with current life-threatening infection at time of transplant that would preclude a transplant are excluded. Concurrent Medication: Excluded: - Other anti-retroviral agents. Patients with current life-threatening infection at time of transplant that would preclude a transplant are excluded. Patients must be: - HTLV III antibody positive by ELISA or Western blot or HTLV III viremia. - At high mortal risk with a diagnosis of AIDS or AIDS Related Complex (ARC). - Also patient must fall into one of the following categories: - Have an HIV seronegative identical twin to serve as a bone marrow donor. - Have documentation of large cell/diffuse histiocytic lymphoma/DPDL. - Be a good risk candidate for bone marrow transplant.", "gender": "All", "minimum_age": "12 Years", "maximum_age": "50 Years", "healthy_volunteers": "No", "id": "NCT00002284.xml"}